A Novel Marker of Inflammation: Azurocidin in Patients with ST Segment Elevation Myocardial Infarction
Open Access
- 29 November 2018
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (12) , 3797
Abstract
(1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI.Keywords
This publication has 32 references indexed in Scilit:
- The relationship between neutrophil to lymphocyte ratio, platelet to lymphocyte ratio and thrombolysis in myocardial infarction risk score in patients with ST elevation acute myocardial infarction before primary coronary interventionAdvances in Interventional Cardiology, 2015
- Inflammation and its Resolution as Determinants of Acute Coronary SyndromesCirculation Research, 2014
- Global and regional burden of disease and risk factors, 2001: systematic analysis of population health dataThe Lancet, 2006
- Simple Risk Stratification at Admission to Identify Patients With Reduced Mortality From Primary AngioplastyCirculation, 2005
- Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial InfarctionJACC, 2005
- Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score)The American Journal of Cardiology, 2004
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003
- Inflammation in atherosclerosisNature, 2002
- TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at PresentationCirculation, 2000